Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting PR Newswire SAN DIEGO, June 20, 2013 SAN DIEGO, June 20, 2013 /PRNewswire/ --Orexigen^® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave^® (naltrexone sustained release (SR) /bupropion SR) clinical data presentations taking place at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013. ADA: McCormick Place Convention Center (West Building), Chicago, IL Abstract# 1056-P – "Combination Naltrexone/Bupropion Therapy Resulted in Clinically Meaningful Improvements in Weight and Quality of Life - Integrated Analysis of Four Phase 3 Trials" Lead Author: Ronette L. Kolotkin Abstract# 1130-P – "An Integrated Analysis of Weight Loss with Combination Naltrexone/Bupropion Therapy by BMI (Obesity) Classification" Lead Author: Caroline M. Apovian Abstract# 1149-P – "Early Improvement in Control of Eating Is Associated with Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of Combination Naltrexone/Bupropion Treatment" Lead Author: Ken Fujioka All abstracts will be presented at General Poster Session 2, on Sunday, June 23, from 12:00 PM - 2:00 PM, in Hall F1 – Posters. Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the Innovative Oral Agents–Innovative Discoveries session on Monday, June 24, from 1:00 PM - 2:00 PM. About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact: Media Contact: McDavid Stilwell Denise Powell VP, Corporate Communications and Business Development BrewLife (858) 875-8629 (510) 703-9491 SOURCE Orexigen Therapeutics, Inc. Website: http://www.orexigen.com
Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Press spacebar to pause and continue. Press esc to stop.